Literature DB >> 17315542

Glucuronidation of DRF-6574, hydroxy metabolite of DRF-4367 (a novel COX-2 inhibitor) by pooled human liver, intestinal microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT1A1, 1A3 and 1A8.

Syed Muzeeb1, Shaik Jafar Sadik Basha, Dhanya Shashikumar, Ramesh Mullangi, Nuggehally R Srinivas.   

Abstract

DRF-4367 is a novel COX-2 inhibitor, which showed good efficacy in several animal models of inflammation. In a comparative in vitro metabolism in various liver microsomes, DRF-4367 forms a hydroxy metabolite (DRF-6574) mediated by CYP2D6 and 2C19 isoenzymes. DRF-6574 readily undergoes Phase-II metabolism and forms glucuronide and sulfate conjugates both in vitro and in vivo. The objective of the present study was two folds: to study the glucuronidation of DRF-6574 in human liver and intestinal microsomes and to identify the recombinant human liver and intestinal UDP-glucuronosyltransferase (UGT) enzymes responsible for glucuronidation of DRF-6574. Of twelve recombinant UGTs tested, two hepatic UGTs viz., UGT1A1 and 1A3 and an extra hepatic UGT i.e., UGT1A8 showed the catalytic activity. The enzyme kinetics in pooled human liver, intestinal and recombinant UGT microsomes showed a typical Michaelis-Menten plot. The apparent Km and Vmax value for DRF-6574 was found to be 116 +/- 24 microM and 2.07 +/- 0.12 microg/min/mg protein and 142 +/- 17 microM and 3.83 +/- 0.15 microg/min/mg protein in pooled human liver and intestinal microsomes, respectively. The intrinsic clearance (Vmax/Km) value for DRF-6574 was estimated to be 0.043 and 0.065 ml/min/mg protein, respectively in pooled human liver and intestinal microsomes. Moreover we have determined the Km and Vmax and intrinsic clearance values for specific UGTs viz., UGT 1A1, 1A3 and 1A8. The apparent Km and Vmax values are 23 +/- 7.2 microM, 3.44 +/- 0.17 microg/min/mg protein for UGT1A1, 60 +/- 7.9 microM, 3.67 +/- 0.11 microg/min/mg protein for UGT1A3, 96 +/- 8.0 microM, 2.95 +/- 0.06 microg/min/mg protein for UGT1A8. The intrinsic clearance values (Vmax/Km) estimated were 0.367, 0.148, 0.074 ml/min/mg protein for UGT1A1, 1A3 and 1A8, respectively. The intrinsic clearance value in UGT1A8 was very close to that in human intestinal and liver microsomes. The formation of DRF-6574 glucuronide by human liver, intestinal and UGT1A1, 1A3 and 1A8 microsomes was effectively inhibited by phenylbutazone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17315542     DOI: 10.1007/BF03190471

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.569


  45 in total

1.  'Open access' generic method for continuous determination of major human CYP450 probe substrates/metabolites and its application in drug metabolism studies.

Authors:  M N V S Rao; B Biju; A K Ansar; S Mujeeb; M Ramesh; N R Srinivas
Journal:  Xenobiotica       Date:  2003-12       Impact factor: 1.908

Review 2.  The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms.

Authors:  D Gail McCarver; Ronald N Hines
Journal:  J Pharmacol Exp Ther       Date:  2002-02       Impact factor: 4.030

3.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin.

Authors:  M B Fisher; K Campanale; B L Ackermann; M VandenBranden; S A Wrighton
Journal:  Drug Metab Dispos       Date:  2000-05       Impact factor: 3.922

Review 4.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence.

Authors:  P I Mackenzie; I S Owens; B Burchell; K W Bock; A Bairoch; A Bélanger; S Fournel-Gigleux; M Green; D W Hum; T Iyanagi; D Lancet; P Louisot; J Magdalou; J R Chowdhury; J K Ritter; H Schachter; T R Tephly; K F Tipton; D W Nebert
Journal:  Pharmacogenetics       Date:  1997-08

Review 5.  Cyclooxygenase inhibitors--current status and future prospects.

Authors:  G Dannhardt; W Kiefer
Journal:  Eur J Med Chem       Date:  2001-02       Impact factor: 6.514

Review 6.  UDP-glucuronosyltransferases and clinical drug-drug interactions.

Authors:  Tony K L Kiang; Mary H H Ensom; Thomas K H Chang
Journal:  Pharmacol Ther       Date:  2005-01-12       Impact factor: 12.310

7.  Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.

Authors:  Yue-Hua Huang; Alema Galijatovic; Nghia Nguyen; Donald Geske; Deirdre Beaton; Judith Green; Mark Green; Wilbert H Peters; Robert H Tukey
Journal:  Pharmacogenetics       Date:  2002-06

8.  2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl]-1-benzenesulfonamide (DRF-4367): an orally active COX-2 inhibitor identified through pharmacophoric modulation.

Authors:  Sunil Kumar Singh; Saibaba Vobbalareddy; Srinivasa Rao Kalleda; Shaikh Abdul Rajjak; Seshagiri Rao Casturi; Srinivasa Raju Datla; Rao N V S Mamidi; Ramesh Mullangi; Ravikanth Bhamidipati; Rajagopalan Ramanujam; Venkateswarlu Akella; Koteswar Rao Yeleswarapu
Journal:  Org Biomol Chem       Date:  2004-08-11       Impact factor: 3.876

9.  Functional polymorphisms of UDP-glucuronosyltransferases 1A1, 1A6 and 1A8 are not involved in chronic pancreatitis.

Authors:  Mariette Verlaan; René H M te Morsche; Akos Pap; Robert J F Laheij; Jan B M J Jansen; Wilbert H M Peters; Joost P H Drenth
Journal:  Pharmacogenetics       Date:  2004-06

Review 10.  Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches.

Authors:  John O Miners; Paul A Smith; Michael J Sorich; Ross A McKinnon; Peter I Mackenzie
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.